红细胞生成素抵抗及其介导纯红细胞再生障碍性贫血的诊治新进展  

Recent advances in the erythropoietin resistance and the pure red cell aplasia induced by anti-erythropoietin antibody

作　　者：张舒[1] 董伟[1] 梁馨苓[1] 

机构地区：[1]广东省人民医院肾内科,广东省医学科学院,广州510080

出　　处：《中国血液净化》2017年第8期512-515,共4页Chinese Journal of Blood Purification

基　　金：国家临床重点专科建设项目国家自然科学基金(81570609)

摘　　要：目前贫血仍是导致慢性肾脏病(chronic kidney disease,CKD)患者死亡的常见并发症之一,尽管红细胞生成素(erythropoietin,EPO)得到广泛应用并改善了CKD患者的贫血,但仍有部分患者因存在EPO抵抗而难以维持理想的血红蛋白水平,甚至极少数患者出现抗EPO抗体介导的纯红细胞再生障碍性贫血(pure red cell aplasia,PRCA)。因EPO抵抗及其介导的PRCA发病机制及临床诊疗尚不十分明确,导致发病率有逐年增加趋势。本文就EPO抵抗及其介导的PRCA近期研究进展进行介绍。Anemia is one of the common complications in chronic kidney disease （CKD） patients. Al- though erythropoietin-stimulating agents （ESAs） have been widely applied and are effective for anemia in CKD patents, it is impossible for some patients to maintain hemoglobin to the recommended level. Pure red cell aplasia （PRCA） induced by anti-erythropoietin antibody is present in a few cases. The pathogenesis of EPO resistance and anti-EPO antibody induced PRCA are unclear, and the prevalence of these abnormalities become increased. Here we discuss the recent advances in EPO resistance and anti-erythropoietin antibody in- duced PRCA.

关 键 词：红细胞生成素 纯红细胞再生障碍性贫血 慢性肾脏病 

分 类 号：R459.5[医药卫生—治疗学]